Follow the growing clinical, research, and international reach of the Montreal Model through news, media, and institutional features.
Featured
LA PRESSE CANADIENNE · JUNE 2025
Dépression: l’efficacité du « modèle de Montréal » est prouvée par une étude
Kyle Greenway and Nicolas Garel discuss the Montreal Model, findings from the MUSIK trial, and its growing use beyond Montreal.
International Developments
The Montreal Model is increasingly informing clinical practice, research, and professional education beyond Montreal.
United Kingdom 🇬🇧
Norway 🇳🇴
Australia 🇦🇺
An NHS adaptation of the Montreal Model
CIM-KeT (CNWL–Imperial–Montreal Ketamine Therapy) adapts the Montreal Model for the UK healthcare system and is currently being piloted at the CIPPRes Clinic at Imperial College London and CNWL.
A parallel model at national scale
In 2025, Norway introduced nationwide public reimbursement for intravenous ketamine treatment for treatment-resistant depression. Its integrated approach, combining ketamine with preparation, music, and psychotherapy, has been described in peer-reviewed literature as closely resembling the Montreal Model.
Clinical education and knowledge exchange
In May 2026, Dr. Nicolas Garel delivered a two-day workshop hosted by Aurora Healthcare at Belmont Private Hospital in Brisbane, bringing together psychiatrists from across the Aurora network and drawing on his experience co-developing the Montreal Model.
Podcasts
In the news
“Le bon et le mauvais de la kétamine”
LaPresse – June 20, 2025
“Les espoirs brisés de la kétamine au privé”
LaPresse – March 25, 2024
“A patient who tried psychedelic therapy said hallucinations of Disney imagery ‘hijacked’ her experience, blaming her habit of spending 6 hours a day trading Disney pins online.”
Business Insider – August 3, 2023
“Canadian woman wanted assisted suicide for depression. Then ketamine saved her.”
National Post – May 17, 2023
English 
French